Merit Medical Reports 9.8% Sales Growth Amid Rising Expenses and Tax Rates in Q1 2025

Merit Medical Systems, Inc. (NASDAQ: MMSI) has released its quarterly financial report for the three months ending March 31, 2025. The company operates in the medical device industry, focusing on interventional, diagnostic, and therapeutic products.

Positive Highlights:

• Net Sales: Increased by 9.8% to $355.4 million from $323.5 million in the prior year.
• Gross Profit Margin: Improved to 48.4%, up from 46.9% year-over-year.
• Net Income: Rose to $30.1 million, or $0.49 per share, compared to $28.2 million, or $0.48 per share in the prior year.
• Cash Position: As of March 31, 2025, cash, cash equivalents, and restricted cash totaled $397.6 million, with an additional borrowing capacity approximately $697 million.
• Growth in segments: Cardiovascular segment sales rose by 8.1% and endoscopy products saw a dramatic 64.2% growth fueled by the acquisition of the EsophyX® Z+ device.

Negative Aspects:

• Operating Expenses: Selling, general, and administrative expenses increased 13.8% to $107.5 million, driven by higher labor costs and promotional expenses.
• Other Income: Interest income fell to $3.8 million from $7.3 million, reflecting reduced cash balances.
• Higher Tax Expense: Income tax expense increased to $7.8 million, leading to a higher effective tax rate of 20.6% compared to 17.8% in the prior year.
• Contingent Consideration: The company recorded a contingent consideration expense of $1.0 million, up from a benefit of $0.1 million the previous year, reflecting changes in the estimated fair value of obligations from acquisitions.

Key Statistics:

• Net Sales: $355.4 million
• Gross Profit: $172.0 million
• Operating Income: $41.0 million
• Diluted EPS: $0.49
• Research and Development Expenses: $22.5 million

Merit Medical continues its trend of increasing revenues, primarily driven by strong performance in its cardiovascular and endoscopy segments, alongside strategic acquisitions. However, rising operating expenses and increased taxes may impact profit margins in the upcoming quarters. The management remains optimistic about ongoing product development and the potential for future revenue growth despite existing trade policy challenges.